Details for Patent: 10,689,377
✉ Email this page to a colleague
Which drugs does patent 10,689,377 protect, and when does it expire?
Patent 10,689,377 protects KRAZATI and is included in one NDA.
This patent has thirty-six patent family members in twenty-nine countries.
Summary for Patent: 10,689,377
| Title: | KRas G12C inhibitors |
| Abstract: | The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor. |
| Inventor(s): | Blake James F., Burgess Laurence E., Chicarelli Mark Joseph, Christensen James Gail, Cook Adam, Fell Jay Bradford, Fischer John P., Marx Matthew Arnold, Mejia Macedonio J., Savechenkov Pavel, Vigers Guy P. A., Smith Christopher Ronald, Rodriguez Martha E. |
| Assignee: | |
| Application Number: | US16191190 |
|
Patent Claim Types: see list of patent claims |
Recent additions to Drugs Protected by US Patent 10,689,377
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirati Theraps | KRAZATI | adagrasib | TABLET | 216340 | Dec 12, 2022 | RX | Yes | ⤷ Sign Up | Y | Y | ⤷ Sign Up | U-3490 | TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY | |
| Mirati Theraps | KRAZATI | adagrasib | TABLET | 216340 | Dec 12, 2022 | RX | Yes | ⤷ Sign Up | Y | Y | ⤷ Sign Up | U-3953 | TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,689,377
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirati Theraps | KRAZATI | adagrasib | TABLET;ORAL | 216340-001 | Dec 12, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,689,377
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3710439 | ⤷ Sign Up | 301279 | Netherlands | ⤷ Sign Up |
| Australia | 2018369759 | ⤷ Sign Up | |||
| Brazil | 112020009818 | ⤷ Sign Up | |||
| Canada | 3082579 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
